Why defer blood donor candidates because of an exposure risk to Chagas disease?;Pourquoi ajourner au don de sang des candidats au motif d'un risque de maladie de Chagas ?

Transfusion Clinique et Biologique

Volumn 15, Issue 3, 2008, Pages 123-128

  Garraud, O ^a,b   Pelletier, B ^b   Aznar, C ^c  

^a UNIVERSITÉ JEAN MONNET   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c UNIVERSITÉ DES ANTILLES ET DE LA GUYANE   (France)

Author keywords

Chagas disease; Hemoparasites; Infectious risk; Prevention; Transfusion; Trypanosoma cruzi

Indexed keywords

ARTICLE; BLOOD DONOR; BLOOD PARASITE; BLOOD TRANSFUSION; CHAGAS DISEASE; DISEASE TRANSMISSION; EXPOSURE; NORTH AMERICA; RISK ASSESSMENT; SOUTH AMERICA; TRYPANOSOMA CRUZI;

BLOOD DONORS; BLOOD TRANSFUSION; CHAGAS DISEASE; DISEASE TRANSMISSION, HORIZONTAL; FRANCE; HUMANS; MALARIA; PARASITEMIA; RISK; SOUTH AMERICA;

EID: 47949098477     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2008.05.003     Document Type: Article

References (48)

1. Faber J.C. The European Blood Directive: a new era of blood regulation has begun. Transfus Med 14 (2004) 257-273
2. McDonald C.P. Bacterial risk reduction by improved donor arm disinfection, diversion and bacterial screening. Transfus Med 16 (2006) 381-396
3. Lefrere J.J., Loiseau P., Maury J., Lasserre J., Mariotti M., Ravera N., et al. Natural history of GBV-C/hepatitis G virus (HGV) infection through the follow-up of GBV-C/HGV-infected blood donors and recipients studied by RNA PCR and anti-E2 serology. Blood 90 (1997) 3776-3780
4. El Ghouzzi M.H., and Garraud O. Parasites et transfusion sanguine : causes et conséquences. Hematologie (Paris) 12 (2006) 129-139
5. Pelloux H., Aznar C., and Bouteille B. Trypanosomiases. Rev Prat 56 (2006) 2209-2216
6. http://www.paho.org/english/hcp/hct/dch/chagas.htm. (Consulté en septembre 2007).
7. Schmunis G.A. The globalization of Chagas disease. ISBT Science Series 2 (2007) 6-11
8. Gascon J., Albajar P., Canas E., Flores M., Gomez i Prat J., Herrera R.N., et al. Diagnosis, management and treatment of chronic Chagas' disease in areas where Trypanosoma cruzi infection is not endemic. Rev Esp Cardiol 60 (2007) 285-293
9. Prata A. Clinical and epidemiological aspects of human Chagas disease. Lancet Infect Dis 1 (2001) 92-100
10. Kotton C.N. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis 44 (2007) 857-866
11. Buekens P., Almendares O., Carliler Y., Dumonteil E., Eberhard M., Gamboa-Leon R., et al. Mother-to-child transmission of Chagas' disease in North America: Why don't we do more?. Matern Child Health 12 (2007) 283-286
12. Camandaroba E.L., Pinheiro Lima C.L., and Andrade S.G. Oral transmission of Chagas disease: importance of Trypanosoma cruzi biodeme in the intragastric experimental infection. Rev Inst Med Trop Sao Paulo 44 (2002) 97-103
13. Acosta Rodriguez E.V., Zuniga E.I., Montes C.L., Merino M.C., Bermejo D.A., Amezcua Vesely M.C., et al. Trypanosoma cruzi infection beats the B-cell compartment favouring parasite establishement: Can we strike first?. Scand J Immunol 66 (2007) 137-142
14. Teixeira A.R., Nitz N., Guimaro M.C., Gomes C., and Santos-Buch C.A. Chagas disease. Postgrad Med J 8 (2006) 788-798
15. Golgher D., and Gazzinelli R.T. Innate and acquired immunity in the pathogenesis of Chagas disease. Autoimmunity 37 (2004) 399-409
16. Leiby D.A. Threats to blood safety posed by emerging protozoan pathogens. Vox Sang 87s2 (2004) 120-122
17. Blajchman T.A. The clinical benefits of the leukoreduction of blood products. J Trauma 60 (2006) S83-S90
18. Gomes M.L., Galvao L.M., Macedo A.M., Pena S.D., and Chiari E. Chagas' disease diagnosis: comparative analysis of parasitologic, molecular, and serologic methods. Am J Trop Med Hyg 60 (1999) 205-210
19. Anez N., Crisante G., and Rojas A. Update on Chagas disease in Venezuela - a review. Mem Inst Oswaldo Cruz 99 (2004) 781-787
20. Mendes D.G., Lauria-Pires L., Nitz N., Lozzi S.P., Nascimento R.J., Monteiro P.S., et al. Exposure to mixed asymptomatic infections with Trypanosoma cruzi, Leishmania braziliensis and Leishmania chagasi in the human population of the greater Amazon. Trop Med Int Health 12 (2007) 629-633
21. Cohen J.E., and Gurtler R.E. Modeling household transmission of American trypanosomiasis. Science 293 (2001) 694-698
22. Malan A.K., Avelar E., Litwin S.E., Hill H.R., and Litwin C.M. Serological diagnosis of Trypanosoma cruzi: evaluation of three enzyme immunoassays and an indirect immunofluorescent assay. J Med Microbiol 55 (2006) 171-178
23. Gutierrez R., Angulo V.M., Tarazona Z., Britto C., and Fernandes O. Comparison of four serological tests for the diagnosis of Chagas disease in a Colombian endemic area. Parasitology 12 (2004) 439-444
24. Berrizbeitia M., Ndao M., Bubis J., Gottschalk M., Ache A., Lacouture S., et al. Field evaluation of four novel enzyme immunoassays for Chagas' disease in Venezuela blood banks: comparison of assays using fixed-epimastigotes, fixed-trypomastigotes or trypomastigote excreted-secreted antigens from two Trypanosoma cruzi strains. Transfus Med 16 (2006) 419-431
25. World Health Organisation. Control of Chagas disease. Second report of the WHO Expert Committee, 2002, Geneva. Technical Reports Series No. 905.
26. Garraud O. Mechanisms of transfusion-linked parasite infection. Transfus Clin Biol 13 (2006) 290-297
27. Bryant B.J., and Klein H.G. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 131 (2007) 719-733
28. Comeau P. Canadian Blood Services to screen for Chagas disease. CMAJ 177 (2007) 242
29. Centers for Disease Control and Prevention (CDC). Blood donor screening for chagas disease - United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2007;56:141-3.
30. Garraud O., Perraut R., Riveau G., and Nutman T.B. Class and subclass selection in parasite-specific antibody responses. Trends Parasitol 19 (2003) 300-304
31. Pirard M., Iihoshi N., Boelaert M., Basanta P., Lopez F., and Van der Stuyft P. The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion 45 (2005) 554-561
32. Silveira-Lacerda E.P., Silva A.G., Junior S.F., Souza M.A., Kesper N., Botelho-Filho A., et al. Chagas' disease: application of TESA-blot in inconclusive sera from a Brazilian blood bank. Vox Sang 87 (2004) 204-207
33. Gadelha A.A., Vercosa A.F., Lorena V.M., Nakazawa M., Carvalho A.B., Souza W.V., et al. Chagas' disease diagnosis: comparative analysis of recombinant ELISA with conventional ELISA and the haemagglutination test. Vox Sang 85 (2003) 165-170
34. De Pina J.J., Garnotel E., Hance P., Vedy S., Rogier C., and Morillon M. Diagnostic du paludisme d'importation en France. Med Mal Infect 37 (2007) 710-715
35. Young C., Losikoff P., Chawla A., Glasser L., and Forman E. Transfusion-acquired Trypanosoma cruzi infection. Transfusion 47 (2007) 540-544
36. Leiby D.A., Lenes B.A., Tibbals M.A., and Tames-Olmedo M.T. Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. N Engl J Med 341 (1999) 1237-1239
37. Garraud O., Andreu G., Elghouzzi M.H., Laperche S., and Lefrere J.J. Measures to prevent transfusion-associated protozoal infections in non-endemic countries. Travel Med Infect Dis 5 (2007) 110-112
38. Reesink H.W. European strategies against the parasite transfusion risk. Transfus Clin Biol 12 (2005) 1-4
39. Aznar C., La Ruche G., Laventure S., Carme B., Liegeard P., and Hontebeyrie M. Seroprevalence of Trypanosoma cruzi infection in French Guiana. Mem Inst Oswaldo Cruz 99 (2004) 805-808
40. Bouillon K., Lert F., Sitta R., Schmaus A., Spire B., and Dray-Spira R. Factors correlated with disclosure of HIV infection in the French Antilles and French Guiana: results from the ANRS-EN13-VESPA-DFA Study. AIDS 21 S1 (2007) S89-S189
41. Soler C.P., Gerome P., Soullie B., Tissedre F., Bejan H., Yvetot J., et al. Comparaison de techniques de dépistages d'anticorps anti-paludiques utilisées en transfusion. Med Trop (Mars) 63 (2003) 587-589
42. Jeannel D, Pillonel J. Maladie de Chagas : estimation du risque transfusionnel lié aux donneurs avec une exposition potentielle à Trypanosoma cruzi. InVS, 2007.
43. Kerleguer A., Massard S., Janus G., and Joussemet M. Maladie de Chagas : évaluation des tests de dépistage dans un centre de transfusion des armées. Pathol Biol (Paris) 55 (2007) 534-538
44. Murphy W. Managing threats rather than risks in blood transfusion: robust design for a complex system. Transfusion 46 (2006) 2011-2013
45. Alter H.J., Stramer S.L., and Dodd R.Y. Emerging infectious diseases that threaten the blood supply. Semin Hematol 44 (2007) 32-41
46. Rojas A., Vinhaes M., Rodriguez M., Monroy J., Persaud N., and Aznar C. International meeting on surveillance and prevention of the Chagas disease in the Amazonia: implementation of intergovernment initiative, Manaus, State of Amazon, 19-22 September 2004. Rev Soc Bras Med Trop 38 (2005) 82-89
47. Corash L. Pathogen reduction technology: methods, status of clinical trials, and future prospects. Curr Hematol Rep 2 (2003) 495-502
48. Flores-Chávez M., Fernández B., Punte S., Torres P., Rodriguez M., Monedero C., Cruz I., Gárate T., Cañavate C., et al. Transfusional Chagas disease: parasitological and serological monitoring of an infected recipient and blood donor. Clin Infect Dis 46 (2008) e44-e47